Table 3 Factors associated with therapeutic response in patients evaluated at M12
From: Rituximab for auto-immune alveolar proteinosis, a real life cohort study
|  | Improved (n = 4) | Non-improved (n = 7) | p-value |
|---|---|---|---|
Age | 47 (41–51) | 48 (30–59) | 0.70 |
Gender male | 4 (100%) | 4 (57%) | 0.24 |
Toxics inhalation or significant smoking | 3 (75%) | 5 (71%) | 1.0 |
Prior treatments to rituximab | 1 (25%) | 7 (100%) | 0.02 |
Severity | |||
 PaO2 (mmHg) | 64.3 (63–66) | 70.7 (57–82) | 0.07 |
 D(A-a)O2 (mmHg) | 42.4 (36.7–46) | 39.4 (31.7–57.7) | 0.32 |
 VC (%) | 94.3 (85–105) | 83.0 (54–95) | 0.92 |
 DLCO (%) | 49.0 (19–64) | 56.9 (38–92) | 0.30 |
 CT-grade | 17.8 (12–23) | 20.1 (14–28) | 0.50 |
Serum anti-GM-CSF | |||
 ELISA (μg/mL) | 169.3 (78–220) | 58.2 (18–104) | 0.03 |
 Functional (titer) | 1566.7 (300–4000) | 496.7 (200–800) | 1.0 |